Versor Investments LP Invests $1.68 Million in Hologic, Inc. (NASDAQ:HOLX)

Versor Investments LP bought a new position in Hologic, Inc. (NASDAQ:HOLX - Free Report) in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 20,590 shares of the medical equipment provider's stock, valued at approximately $1,677,000.

Several other hedge funds also recently made changes to their positions in HOLX. Price T Rowe Associates Inc. MD lifted its position in Hologic by 77.7% in the first quarter. Price T Rowe Associates Inc. MD now owns 6,297,197 shares of the medical equipment provider's stock valued at $490,931,000 after purchasing an additional 2,753,016 shares during the period. The Manufacturers Life Insurance Company lifted its holdings in shares of Hologic by 21.6% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 2,535,258 shares of the medical equipment provider's stock valued at $188,243,000 after buying an additional 450,190 shares during the period. Black Creek Investment Management Inc. lifted its holdings in shares of Hologic by 60.9% in the 2nd quarter. Black Creek Investment Management Inc. now owns 2,338,970 shares of the medical equipment provider's stock valued at $173,669,000 after buying an additional 885,524 shares during the period. Dimensional Fund Advisors LP grew its holdings in Hologic by 5.7% during the second quarter. Dimensional Fund Advisors LP now owns 2,326,992 shares of the medical equipment provider's stock worth $172,780,000 after acquiring an additional 124,739 shares during the period. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. raised its position in Hologic by 4.0% in the second quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 2,271,603 shares of the medical equipment provider's stock worth $168,666,000 after acquiring an additional 87,176 shares in the last quarter. Institutional investors and hedge funds own 94.73% of the company's stock.

Hologic Trading Up 0.8 %

Shares of NASDAQ:HOLX traded up $0.63 during trading on Monday, reaching $79.39. The stock had a trading volume of 1,219,868 shares, compared to its average volume of 1,591,541. Hologic, Inc. has a fifty-two week low of $67.59 and a fifty-two week high of $84.67. The business has a fifty day moving average price of $80.97 and a 200-day moving average price of $78.16. The stock has a market cap of $18.44 billion, a P/E ratio of 23.65, a PEG ratio of 2.48 and a beta of 0.98. The company has a quick ratio of 3.32, a current ratio of 3.69 and a debt-to-equity ratio of 0.49.

Hologic (NASDAQ:HOLX - Get Free Report) last issued its quarterly earnings results on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share for the quarter, hitting analysts' consensus estimates of $1.01. The company had revenue of $987.90 million for the quarter, compared to analyst estimates of $978.25 million. Hologic had a return on equity of 19.79% and a net margin of 19.59%. The business's revenue for the quarter was up 4.5% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.89 EPS. As a group, analysts anticipate that Hologic, Inc. will post 4.27 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

HOLX has been the topic of a number of recent analyst reports. Stephens reaffirmed an "overweight" rating and set a $92.00 price target on shares of Hologic in a research note on Tuesday, July 30th. Citigroup cut shares of Hologic from a "buy" rating to a "neutral" rating and dropped their target price for the company from $95.00 to $85.00 in a report on Tuesday, October 1st. UBS Group upped their price target on Hologic from $84.00 to $90.00 and gave the stock a "neutral" rating in a report on Tuesday, November 5th. StockNews.com downgraded Hologic from a "buy" rating to a "hold" rating in a research note on Wednesday, November 6th. Finally, Raymond James boosted their target price on Hologic from $93.00 to $95.00 and gave the stock an "outperform" rating in a research report on Tuesday, November 5th. Six research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $89.25.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.